Bio3 Research S.r.l. (Milan, Italy) seeks Licensees for its Dietary Supplement Biocysan® in the USA

WALTHAM, Mass. - Jan. 14, 2014 - PRLog -- Bio3 Research S.r.l. (Milano, Italy) seeks Licensees for its Dietary Supplement Biocysan® in the USA

Milano, Italy, January 01, 2014 – Bio3 Research S.r.l. announced today that the company is seeking licensees to market its dietary supplement Biocysan® in the USA.

Bio3 Research will be responsible for supplying the finished product to its licensees.

Biocysan® is a proprietary dietary supplement based on oral L-Cysteine in a pulse release formulation; patents have already been granted in the USA, Canada, Mexico and Europe, and a patent is pending in Japan.

L-Cysteine is a precursor of Glutathione (GSH), a tetra-peptide that is a key factor that protects Red Blood Cell walls from breakdown and ultimately allows proper Oxygen transportation in the body.  Biocysan® is a supplement for individuals who are at risk of developing severe anemia due to low GSH levels, and for reducing oxidative stress by re-establishing GSH levels.

Bio3 Research has already obtained a Free Sale Certificate (FSC) for Biocysan® from the Italian Ministry of Health and has started marketing the product in several countries thanks to collaborations established with local distributors.

Bio3 Research will soon start, in collaboration with Mario Negri Institute (Team Prof. Giuseppe Remuzzi – President of International Nephrology Society), a pilot study with Biocysan® in patients under peritoneal dialysis. The pilot study will determine endpoints such as Residual Kidney Function, Glomerular Filtration Rate (GFR) and Glutathione levels. This pilot study is instrumental to confirm the benefits of the product in individuals suffering of anemia and oxidative stress due to impaired kidney functions.

For further information about Biocysan® please refer to the official website www.biocysan.com.

About Bio3 Research S.r.l.:

Bio3 Research s.r.l. develops new proprietary compounds with therapeutic potential in the cardiovascular and connective tissue regeneration fields. The company is developing the protein HMGB1 (High Mobility Group Box 1) for its use in connective-tissue regeneration (diabetic foot ulcer, healing of wounds, burns and bedsores, cartilage repair, bone matrix regeneration). Bio3 Research also develops compounds (HMGB1 fragments) to inhibit/antagonize systemic HMGB1 levels, for use in cardiovascular disorders (restenosis, arterial stenosis, treatment of atherosclerotic plaque progression).  As a separate line of business, Bio3 Research has also developed and markets in several countries Biocysan® (oral L-Cysteine – pulse release formulation), a proprietary dietary supplement to counteract oxidative stress in chronic kidney disease patients and to alleviate anemia.  Additional information on Bio3 Research and on Biocysan can be obtained from www.bio3research.com and www.biocysan.com.

CONTACT: Mr. Federico Gardini, Chief Business Officer, Bio3 Research S.r.l., Phone: +39-0262694888, e-mail: f.gardini@bio3research.com